샘플 요청 목록

 카트 문의
시장보고서
상품코드
1533715

세계의 포도막염 치료제 시장

Uveitis Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 413 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 포도막염 치료제 시장은 2030년까지 12억 달러에 달할 전망

2023년에 8억 8,860만 달러로 추정되는 세계의 포도막염 치료제 시장은 분석 기간인 2023-2030년에 CAGR 4.1%로 성장하며, 2030년에는 12억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 부신피질 스테로이드약은 CAGR 4.6%를 기록하며, 분석 기간 종료시에는 4억 6,900만 달러에 달할 것으로 예측됩니다. Cycloplegic약 부문의 성장률은 분석 기간 중 CAGR 3.3%로 추정됩니다.

미국 시장은 2억 4,210만 달러로 추정, 중국은 CAGR 7.8%로 성장할 것으로 예측

미국의 포도막염 치료제 시장은 2023년에 2억 4,210만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은2023-2030년 CAGR을 7.8%로서 2030년까지 2억 5,180만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.4%와 3.1%로 예측됩니다. 유럽에서는 독일이 CAGR 2.2%로 성장할 것으로 예측됩니다.

세계의 포도막염 치료제 시장 - 주요 동향과 촉진요인 정리

포도막염은 홍채, 모양체, 맥락막을 포함한 안구의 중간층인 포도막에 영향을 미치는 염증성 질환입니다. 이 질환을 방치하면 시력 상실과 같은 심각한 합병증을 유발할 수 있습니다. 포도막염은 감염, 자가면역질환, 독소 노출 등으로 인해 발생할 수 있으며, 눈의 충혈과 통증, 시야 흐림 등 다양한 증상이 나타날 수 있습니다. 포도막염 치료의 주요 목표는 염증을 억제하고 통증을 관리하며 조직의 추가 손상을 방지하는 것입니다. 포도막염 치료에 사용되는 약물에는 부신피질 스테로이드제, 면역억제제, 생물학적 제제, 비스테로이드성 항염증약(NSAIDs) 등이 있습니다.

최근 수년간 포도막염 치료제 시장은 괄목할 만한 발전과 다양화를 이룩했습니다. 코르티코스테로이드와 같은 전통적인 치료법은 강력한 항염증 효과로 인해 급성 염증을 관리하는 데 있으며, 여전히 주요한 역할을 하고 있습니다. 그러나 스테로이드의 장기 사용은 부작용을 유발할 수 있으며, 대체 요법의 개발이 요구되고 있습니다. 메토트렉세이트나 사이클로스포린과 같은 면역억제제는 면역반응을 조절하기 위해 만성질환에 자주 사용되고 있습니다. 또한 아달리무맙과 같은 TNF 억제제를 포함한 생물학적 제제의 등장은 전신 부작용이 적고 표적화된 작용을 제공함으로써 치료의 전망을 바꾸어 놓았습니다. 이러한 생물학적 제제는 난치성 포도막염 환자나 기존 치료법을 견디지 못하는 환자들에게 특히 유용합니다. 또한 유리체강내 주사 및 서방형 임플란트와 같은 새로운 약물전달 시스템은 포도막염 관리의 효과와 편의성을 향상시키고 있습니다.

포도막염 치료제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 포도막염의 주요 위험 요인인 자가면역질환과 감염성 질환의 유병률이 증가함에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다. 둘째, 생명공학 및 의약품의 발전으로 혁신적인 생물학적 제제 및 표적 치료제가 개발되어 환자들에게 더 많은 치료 옵션을 제공합니다. 또한 포도막염에 대한 인식과 진단이 높아짐에 따라 보다 조기에 적극적인 치료 접근이 가능해져 시장 수요를 더욱 촉진하고 있습니다. 신흥 시장에서의 의료 인프라 확충은 포도막염 치료에 대한 접근성을 향상시켜 시장 성장에 기여하고 있습니다. 또한 제약회사와 연구기관의 전략적 제휴로 인해 신약 및 치료법 개발이 가속화되고 있습니다. 마지막으로 희귀질환 치료제 및 포도막염과 같은 희귀질환 치료에 대한 규제 당국의 지원과 신속한 승인 절차가 이 분야의 혁신과 투자를 촉진하고 있습니다.

조사 대상 기업의 예(총 74건)

  • AbbVie, Inc.
  • AdvaCare Pharma
  • Alcon, Inc.
  • Alimera Science Inc.
  • Bausch+Lomb Corporation
  • Clearside Biomedical inc.
  • Fera Pharmaceuticals
  • Kiora Pharmaceuticals, Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Merck & Co. Inc.
  • Novartis International AG
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd
  • Tarsier Pharma Ltd;

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 24.08.30

Global Uveitis Drugs Market to Reach US$1.2 Billion by 2030

The global market for Uveitis Drugs estimated at US$888.6 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. Corticosteroid Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$469.0 Million by the end of the analysis period. Growth in the Cycloplegic Agents segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$242.1 Million While China is Forecast to Grow at 7.8% CAGR

The Uveitis Drugs market in the U.S. is estimated at US$242.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$251.8 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Uveitis Drugs Market - Key Drivers and Trends Summarized

 

Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye, which includes the iris, ciliary body, and choroid. This condition can lead to severe complications, including vision loss if left untreated. Uveitis can be caused by infections, autoimmune disorders, or exposure to toxins, and its symptoms range from eye redness and pain to blurred vision. The primary goal of uveitis treatment is to reduce inflammation, manage pain, and prevent further tissue damage. The drugs used for treating uveitis include corticosteroids, immunosuppressants, biologics, and nonsteroidal anti-inflammatory drugs (NSAIDs).

The uveitis drugs market has witnessed significant advancements and diversification over recent years. Traditional treatments like corticosteroids remain the mainstay for managing acute inflammation due to their potent anti-inflammatory properties. However, long-term use of steroids can lead to adverse effects, prompting the development of alternative therapies. Immunosuppressants, such as methotrexate and cyclosporine, are increasingly used for chronic cases to modulate the immune response. Furthermore, the advent of biologics, including TNF inhibitors like adalimumab, has revolutionized the treatment landscape by offering targeted action with fewer systemic side effects. These biologics are particularly beneficial for patients with refractory uveitis or those who cannot tolerate conventional treatments. Additionally, novel drug delivery systems, such as intravitreal injections and sustained-release implants, have improved the efficacy and convenience of uveitis management.

The growth in the uveitis drugs market is driven by several factors. Firstly, the increasing prevalence of autoimmune disorders and infectious diseases, which are major risk factors for uveitis, has escalated the demand for effective treatments. Secondly, advancements in biotechnology and pharmaceuticals have led to the development of innovative biologics and targeted therapies, enhancing treatment options for patients. Additionally, the rising awareness and diagnosis of uveitis have resulted in earlier and more aggressive treatment approaches, further boosting market demand. The expansion of healthcare infrastructure in emerging markets has also improved access to uveitis treatments, contributing to market growth. Furthermore, strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of new drugs and therapies. Lastly, regulatory support and expedited approval processes for orphan drugs and treatments for rare diseases like uveitis are encouraging innovation and investment in this field.

Select Competitors (Total 74 Featured) -

  • AbbVie, Inc.
  • AdvaCare Pharma
  • Alcon, Inc.
  • Alimera Science Inc.
  • Bausch + Lomb Corporation
  • Clearside Biomedical inc.
  • Fera Pharmaceuticals
  • Kiora Pharmaceuticals, Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Merck & Co. Inc.
  • Novartis International AG
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd
  • Tarsier Pharma Ltd;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Uveitis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Uveitis Drives Market Demand for Effective Drugs
    • Advancements in Drug Delivery Systems Enhance Efficacy and Patient Compliance
    • Growing Awareness of Ocular Health Boosts Demand for Uveitis Treatments
    • Expansion of Ophthalmology Clinics and Specialty Centers Increases Market Reach
    • Development of Biologic Therapies Attracts Investment in Uveitis Drug Research
    • Increasing Use of Immunosuppressive Agents in Uveitis Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Uveitis Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Uveitis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Uveitis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Uveitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cycloplegic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cycloplegic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cycloplegic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunosuppressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunosuppressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Anterior Uveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Anterior Uveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Anterior Uveitis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Intermediate Uveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Intermediate Uveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Intermediate Uveitis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Panuveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Panuveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Panuveitis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Posterior Uveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Posterior Uveitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Posterior Uveitis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • JAPAN
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • CHINA
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • EUROPE
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Uveitis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Uveitis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Uveitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • FRANCE
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • GERMANY
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Uveitis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Uveitis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Uveitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • INDIA
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Uveitis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Uveitis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Uveitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Uveitis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Uveitis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Uveitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030
  • AFRICA
    • Uveitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Uveitis Drugs by Drug Type - Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Uveitis Drugs by Drug Type - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Cycloplegic Agents, Immunosuppressant Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Uveitis Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Uveitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Uveitis Drugs by Disease Type - Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Uveitis Drugs by Disease Type - Percentage Breakdown of Value Sales for Anterior Uveitis Disease, Intermediate Uveitis Disease, Panuveitis Disease and Posterior Uveitis Disease for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제